Pentixapharm Holding AG Plans Rights Issue to Raise EUR 20.4 Million

Pentixapharm Holding AG has announced a rights issue to raise approximately EUR 20.4 million. The company aims to increase its share capital by issuing up to 11,020,212 new shares at a subscription price of EUR 1.85 each, representing a 21% discount on the previous closing price. The subscription period is from July 7 to July 21, 2026. Major shareholder Eckert Wagniskapital, holding nearly 36% of shares, has committed to fully exercise its rights.

The funds will primarily finance the PANDA Phase 3 study evaluating [⁶⁸Ga]Ga-PentixaFor for hypertension treatment due to primary aldosteronism. Additional funds will support the company's U.S. expansion, clinical development, manufacturing, and theranostic platform.